Authors
Latest:
Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell LymphomaChimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.
Latest:
Dr Mazzoni on the Use of Quadruplet Regimens in Newly Diagnosed MyelomaSandra Mazzoni, DO, discusses the emerging role of quadruplet regimens in newly diagnosed multiple myeloma.
Latest:
UW Carbone Cancer Center Receives SPORE Designation, Federal Grant to Support Prostate Cancer ResearchUniversity of Wisconsin Carbone Cancer Center will be designated as a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute for research initiatives to advance new prostate cancer treatments.
Latest:
Dr Lau on Tarlatamab as Maintenance Therapy in Extensive-Stage SCLCSally Lau, MD, discusses the addition of tarlatamab to a PD-L1 inhibitor as first-line maintenance therapy for extensive-stage small cell lung cancer.
Latest:
Dr. Altorki on the Results of Post-Hoc Analyses of the IMpower010 Trial in NSCLCNasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.
Latest:
The Investigational Pipeline for Advanced BTCMilind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.
Latest:
Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable HCCPierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.
Latest:
Dr. Rao on the Rationale of the CASPAR Trial in mCRPCArpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.
Latest:
The Future of HCC TreatmentThe panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.
Latest:
Dr Barzi on the Real-World Use of Triplet Chemotherapies in mCRCAfsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.
Latest:
Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple MyelomaHans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.
Latest:
OncLive Peer Exchange on Allo-HSCT: Conclusion of DiscussionThe expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
Latest:
Dr Shah on Real-World Treatment and Outcomes in Metastatic RCC After IO/TKI CombosNeil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.
Latest:
Dr. Ramos on the Role of BCG In Non-Muscle Invasive Bladder CancerFélix Guerrero-Ramos, MD, PhD, FEBU, discusses the role of Bacillus Calmette-Guerin in the treatment of patients with non-muscle invasive bladder cancer.
Latest:
Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian CancerLucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.
Latest:
Community-Based Programs Have the Power to Remove Clinical Trial BarriersHomogeneous trials present a missed opportunity to discover treatments that might be highly successful in a particular subset of patients.
Latest:
Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCCAnna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.
Latest:
Dr. Yeku on the Evaluation of COM701 Plus Nivolumab in Platinum-Resistant Ovarian CancerOladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.
Latest:
Novel Treatment Advances in Differentiated Thyroid CancerAn overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.
Latest:
Dr Brunner on the Heterogeneity of Relapsed Multiple MyelomaMatthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.
Latest:
CAR T-cells as Third-line and Beyond Therapy for FLBijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Latest:
Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLLChristopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.
Latest:
ESMO 2020 Highlights With Cora Sternberg, MD, FACPTROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.
Latest:
Tumor Agnostic Role of TMB Biomarker Faces ChallengesAlthough tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.
Latest:
Julia “Julie” Borrelli Named Chair of the Abramson Cancer Center Director's Leadership CouncilJulia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council.
Latest:
Dr. Michot on the Examination of CC-99282 in Relapsed/Refractory NHLJean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.
Latest:
Dr Naqash on Combining Abequolixron Plus Docetaxel in Recurrent NSCLCAbdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.
Latest:
Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRCMicheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.
.jpg?fit=crop&auto=format)
